Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Investments (2016 - 2023)

Myriad Genetics (MYGN) has disclosed Long-Term Investments for 14 consecutive years, with $6.2 million as the latest value for Q2 2023.

  • On a quarterly basis, Long-Term Investments fell 92.1% to $6.2 million in Q2 2023 year-over-year; TTM through Jun 2023 was $6.2 million, a 92.1% decrease, with the full-year FY2022 number at $54.8 million, down 7.12% from a year prior.
  • Long-Term Investments was $6.2 million for Q2 2023 at Myriad Genetics, down from $30.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $78.5 million in Q2 2022 to a low of $6.2 million in Q2 2023.
  • A 5-year average of $42.8 million and a median of $45.2 million in 2020 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: soared 494.96% in 2022, then tumbled 92.1% in 2023.
  • Myriad Genetics' Long-Term Investments stood at $47.6 million in 2019, then tumbled by 55.88% to $21.0 million in 2020, then surged by 180.95% to $59.0 million in 2021, then decreased by 7.12% to $54.8 million in 2022, then plummeted by 88.69% to $6.2 million in 2023.
  • Per Business Quant, the three most recent readings for MYGN's Long-Term Investments are $6.2 million (Q2 2023), $30.4 million (Q1 2023), and $54.8 million (Q4 2022).